The collaboration will initially focus on the application of Invitrogen’s media and cell separation technologies for cell product-based applications. This will include the proprietary Dynabeads® separation technology and encompass the new Dynabeads® ClinExVivo™ CD3/CD28 (formerly known as Xcyte™Dynabeads®) developed to optimize ex vivo T cell activation and expansion in translational research while preserving T cell viability and optimal immune function.
The collaboration will comprise co-marketing, co-referrals, joint proposals, and technical consulting services provided by PCT to Invitrogen and its customers.
“With experience in the application of state-of-the art technologies for the therapeutic application of over 20 cell types in dozens of clinical indications, Progenitor Cell Therapy brings a wealth of experience in the development of cells for therapeutic products,“ stated Dr. Oystein Amellem, Business Segment Director for Invitrogen's Dynal Bead Based Separation group. “This includes experience with the Dynabeads® platform and its related technologies, various expansion media and culture systems, including the Wave Bioreactor®. This kind of experience is valuable to Invitrogen in terms of ongoing product development, product testing and validation, as well as customized technical integration and implementation of services for our customers.”
“Invitrogen’s collaboration with a company like PCT is not merely to leverage their experience to enhance our products and sales,” continues Dr. Amellem. “We also believe that the model of centralized development and manufacturing such as PCT provides, will be critical to the successful commercialization of many cell therapy products and the companies developing them.”
“Partnering with life science leaders such as Invitrogen is an important part of PCT’s strategy,” states Dr. Stewart Craig, Progenitor’s Vice-President and Chief Technical Officer. “Our promise to clients is to utilize our extensive experience to provide integrated solutions to their product development and manufacturing needs. Within this, we will make available to them our recommendations for the most applicable best-in-class technologies. Therefore, the closer we can be to the leading technology platforms, the better positioned we are to provide our customers with the most effective technologies for developing and commercializing their cell-based products.”
Dr. Robert A. Preti, Progenitor’s President and Chief Scientific Officer states, “We believe Invitrogen is one of the leading technology providers critical to the success of the field of cell therapy. PCT is committed to integrating solutions such as those provided by Invitrogen for clients’ products.”
About Progenitor Cell Therapy, LLC.
Progenitor Cell Therapy (PCT) is a client-based cell therapy services company that supports the development and commercialization of cellular therapies. PCT provides cGMPcompliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation. For more information, please visit
www.progenitorcelltherapy.com.
About Invitrogen Corporation.
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com.
This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “intend,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.
Contact:
George Goldberger
Chief Business Officer
Progenitor Cell Therapy, LLC
(201) 883-5314
